We're coming into the homestretch of our Fundraising Challenge, but there's still time to earn some Komen swag! Register and raise $31 by July 31 for a Race or Walk to earn an exclusive Komen keychain. Visit komen.org for the full terms and conditions.

Dr. Kimberly Sabelko, Komen's VP of Scientific Strategy and Programs, chats with @oncodaily.bsky.social to discuss our $15.4 million investment in breast cancer research, why MBC is the main focus & how AI is playing a role in breast cancer research. Watch the full interview: https://bit.ly/4yDNX02

A big Congressional victory for the breast cancer community! The Breast Cancer Education and Awareness Requires Learning Young (EARLY) Act Reauthorization of 2025 & the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act passed on the House floor!

The OASIS-4 clinical trial is studying elinzanetant, a new non-hormonal medication, for women who have HR+ breast cancer, or are at high risk for it, and are dealing with hot flashes and night sweats caused by hormone therapy.

GLP-1s are making headlines and breast cancer researchers are paying close attention. A new CURE article featuring insights from Komen staff explores what we know so far, what questions remain and why any decision about GLP-1s should be guided by an oncology care team. https://bit.ly/4fFEJss

GLP-1s: Weight Loss and Survival in Breast Cancer Recovery | CURE

ASCO 2026 findings and patient stories show how GLP-1 drugs improve metabolic health and potentially transform breast cancer survivorship.

bit.ly

Hispanic and Latina women are often diagnosed with later-stage breast cancers than white women, possibly due to delays in follow-up care after an abnormal screening mammogram. It's important to know your risk factors and advocate for yourself. Visit komen.org to learn more.

Chemo brain isn’t random. It’s not “just in your head” -- Estrogen changes and treatment can affect how your brain communicates. Learn the biology behind brain fog in our latest Under the Microscope video. Watch the full episode: https://youtu.be/desV6bWFdyY

Cancer clinical trial enrollment by adults in the U.S. is less than 5%. Breast cancer clinical trials study prevention, new screening tests and treatment options, as well as quality of life issues. Learn more about clinical trials at komen.org or email clinicaltrialinfo@komen.org.

We're proud to have supported investigators who contributed to Phase III clinical trials that led to the latest expanded FDA approval for the use of each drug. You can learn all about these clinical trial results through our Breast Cancer Breakthroughs Series: https://bit.ly/4amC5EZ

Many of today’s most significant advances in breast cancer treatment began as bold, early-stage concepts. We're proud to support innovative research that leverages AI, advanced technologies & new therapies to improve patient outcomes. Learn more about our 2026 Research Grants https://bit.ly/4wriexd

Through clinical trials, researchers are uncovering smarter therapies that help patients live longer, feel better and hold onto the ultimate hope: a future without breast cancer. Learn more about the top breast cancer clinical trials featured at @ascocancer.bsky.social: https://bit.ly/4oHaCDM

The cures are closer than ever. We’re pursuing the right data, the right questions and the treatments to make it possible. That's why today, we're excited to announce this year's $15.4 million investement in research and it's all thanks to your support!

Komen’s Investment in the Future of Breast Cancer Research

Komen is investing in the future of breast cancer research, awarding $15.4 million to researchers working on accelerating breakthroughs.

komen.org

Many men have been where you are today. Social support is important after a breast cancer diagnosis. The Komen Patient Care Center can help you find a support group for you and your loved ones, or resources in your area. Call 1-877-GO KOMEN or email helpline@komen.org. We're here for you.

Tune in to our upcoming episode to learn what's new in imaging for MBC. Bring your questions ready - it's a live Q&A! Dr. David Mankoff will share updated imaging practices for ER+ MBC and new data from a national clinical trial on FDG PET/CT for bone metastases. Register: https://bit.ly/4vebmTo

Let’s talk about male breast cancer. Yes, it happens! Jake Messier is joined by Bret Miller and Richard Loud to talk about how they were initially diagnosed, their treatment plan, and resources that have helped them. Watch our premiere Men’s Health Month episode now: https://youtu.be/HgTyPTCT3HI

Men who get breast cancer are more likely to have an inherited gene mutation than women who get breast cancer. For this reason, genetic testing for BRCA1 a&BRCA2 (BRCA1/2) gene mutations is recommended for all men diagnosed w/ breast cancer. Learn more about genetic testing: https://bit.ly/4amgGvv

Thrilled to see many Komen-supported grantees & posters at #ASCO26. Each reflects scientific progress and the dedication of researchers improving outcomes for people impacted by breast cancer. Proud to support science, moving us closer to a world without breast cancer. @ascocancer.bsky.social

The future of breast cancer care depends on continued groundbreaking discoveries, and there’s incredible work happening right now.

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ascocancer.bsky.social

🧬 Francois Bidard, MD, Ph.D. presents SERENA-6 at #ASCO26: Switching to camizestrant + CDK4/6i when ESR1 mutations emerge during first-line therapy improved outcomes through 2 lines of treatment in HR+/HER2- advanced breast cancer @ascocancer.bsky.social

GLP-1 use is rising but what about #breastcancer risk? Long term safety matters. At #ASCO26, Elizabeth Susan McDonald, MD, PhD reported GLP-1 treatment was associated with lower BC incidence in women, but clinical trials are needed to confirm a true risk reduction effect. @ascocancer.bsky.social

PANKU-Breast02 phase 3 trial: iza-bren vs chemo in pre-treated metastatic TNBC. 📊 Jiong Wu, MD, PhD reported that patients had improved overall survival & stayed progression-free longer with manageable side effects, suggesting iza-bren could become a new standard option. @ascocancer.bsky.social

Can ADCs improve outcomes in pts who can't get immunotherapy? 🤔 At #ASCO26, David Cescon, MD, PhD shared new TROPION-Breast02 data: Dato-DXd helped pts go longer w/o progression & delayed need for further tx vs chemo, supporting it as a potential new 1L standard in mTNBC. @ascocancer.bsky.social

🧬Dr. Kevin Kalinsky presents ASCENT-04 at #ASCO26: Starting on sacituzumab govitecan + pembro upfront led to better outcomes through 2 lines of treatment in PD-L1+ metastatic TNBC - even vs patients who eventually received SG later. @ascocancer.bsky.social

ASCENT-03 tests sacituzumab govitecan (SG) vs chemo in 1L metastatic TNBC Dr. Sara Tolaney presented new data showing improved PFS after next line of treatment & subsequent therapies, supporting SG as a potential new standard of care for those not eligible for PD-L1 therapy. @ascocancer.bsky.social

At #ASCO26, Komen grantee Sharon Giordano, the recipient of the Gianni Bonadonna Breast Cancer Award, shared insights on opportunities, challenges and lessons learned in breast cancer outcomes research 🏆 @ascocancer.bsky.social

Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social

Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social

New biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social

Can some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social